Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Adlai Nortye has dosed the first patient in the intermittent weekly arm of the global Phase 1 trial for AN9025, its oral pan-RAS(ON) inhibitor targeting advanced solid tumors with RAS mutations. The company believes the weekly dosing schedule could widen the therapeutic window, and both the daily and weekly arms of the study are now actively enrolling patients.
Key figures
- Drug Name
- AN9025
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.